The Injectable Drug Delivery market is anticipated to grow from US$ 43.84 billion in 2024 to US$ 75.39 billion by 2031; the market is expected to register a CAGR of 8.2% from 2025 to 2031. The injectable drug delivery market growth is attributed to the rising global burden of chronic diseases, surge in biologics and monoclonal antibodies requiring parenteral administration, and technological advancements in self-injection and patient-centric delivery devices.

The delivery of drugs via injection involves administering drugs through the use of needles or needle-free delivery devices directly into the patient's body. Injectables provide a quick, accurate, and consistent means of administering therapeutic agents to patients. Injectables are an important delivery method for biologics, vaccinations, insulin products, cancer chemotherapy agents, emergency medications, and other medications that cannot be delivered in oral or other traditional routes. AI-driven personalization, advancing lipid nanoparticle injectables for rapid-response vaccines and gene editing, and biodegradable polymers and green packaging in injectable drug systems are expected to be major injectable drug delivery market trends in the coming years.

The injectable drug delivery market in North America is segmented into the US, Canada, and Mexico. The North America injectable drug delivery market is expanding owing to several factors. The US holds the largest market share, followed by Canada. The collaborative innovation in sterile filling and finishing of product components between many of the pharmaceutical companies in order to establish complex biological products like the GLP-1 therapies will be the main focus of this section. In addition, multi-national companies, such as Roche/Genentech and Novartis, have established strategic partnerships with their B2B partners to create subcutaneous delivery systems (self-injectable formats) for oncology drugs (Avastin, Rituxan) that are more user-friendly than intravenous routes, which limit patient compliance, while at the same time increasing the bioavailability of the drug to the patient, allowing them to administer the product at home. This synergy within the healthcare industry provides an efficient process for managing product life-cycles and reduces the burden on the healthcare system by focusing on the user-friendly designs of these products. An example of disruptive technology is Enable Injections' wearable devices that can administer large volumes (up to 50 mL) of viscous biological therapies, which work with biopharmaceutical companies to address key issues of aggregation and viscosity found in monoclonal antibody delivery. This collaboration with pharmaceutical companies provides a means to create scalable solutions to the long-term management of chronic diseases. In addition to Enable Injections, Capsugel Dosage Form Solutions (DFS) also maintains a vertically integrated B2B model. Capsugel collaborates with pharmaceutical and nutritional companies to design encapsulated liquid filling technology through the use of their LIPIDEX platform, providing both rapid and efficient formulations from clinical testing to large-scale production via FDA accredited sites for high containment injectables (i.e., hormones).

Additionally, BD Medical is enhancing the ability to inject beneath the skin through collaborations like its partnership with ten23 health for developing RFID-enabled pre-filled syringes that allow the tracking of products during filling and finishing stages and with Biocorp to create a connected version of the UltraSafe Plus Passive Needle Guard, which will enable the monitoring of patients' use of anticoagulants digitally. The Maggie 5.0 Autoinjector from SHL Medical includes Needle Isolation Technology and is working with oncology-focused pharmaceutical companies to help them customize the gauge used in the delivery system to ensure the best possible timeframes for delivering high doses of Therapeutics. Credence MedSystems offers the Connect system, which allows for remote data logging for prefilled syringes used in clinical studies. Phillips-Medisize is a partner of Bayer on the BETACONNECT platform for treating multiple sclerosis, through which they provide connected auto-injectors that enable a patient's adherence to the treatment by using an app to track the patient's activity. These examples reflect an ecosystem of collaboration between CDMOs and medical device manufacturers who develop each other's platforms together, which allow for smooth integration throughout the various steps required in going from R&D to putting products into distribution, ultimately resulting in increased operational efficiencies within the competitive landscape of the US.

The US Food and Drug Administration, World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), and WHO (World Health Organization) are among the primary and secondary sources referred to while preparing the injectable drug delivery market report.